Table 4.
Baseline parameter | Responders/Evaluable | % |
---|---|---|
Total responders | 14/44 | 32 |
| ||
Prior therapies | ||
No HMA | 1/8 | 13 |
HMA | 13/36 | 36 |
| ||
Baseline cytopenias | ||
1 | 2/19 | 11 |
2–3 | 12/25 | 48 |
| ||
Prior HMA and 2–3 cytopenias | 11/22 | 50 |
| ||
IPSS risk | ||
Low | 2/12 | 17 |
Intermediate-1 | 12/32 | 38 |
| ||
Phospho-p38 MAPK status at Baseline | ||
Positive1 | 7/13 | 54 |
Negative2 | 2/6 | 33 |
Positive defined as ≥ 5% p-p38[+] cells
One patient negative for phospho-p38 MAPK at baseline was not evaluable for HI